Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM

Name: Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM
Uploaded: 2022-04-04T02:00:00+00:00
Duration: 3 min 47 s
Description: ACC 2022 Maya Guglin explains the pathophysiology of hypertrophic cardiomyopathy (HCM) and discusses what the results of the long term extension study of E

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
SCOUT-HCM: Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
Joseph Rossano, MD
- Joseph Rossano, MD
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
ACC 2026 Clinical Insights: Advancing Cardiovascular Care
Hypertrophic Cardiomyopathy: Moving From Monitoring to Action in the Era of Myosin Inhibitors
Joseph Rossano, MD
- Joseph Rossano, MD
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Hypertrophic Cardiomyopathy
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
Ahmad Masri, MD, MS
- Ahmad Masri, MD, MS
Mavacamten in symptomatic non-obstructive HCM
Mavacamten in symptomatic non-obstructive HCM
ESC Congress 2025
Mavacamten in symptomatic non-obstructive HCM
Milind Desai, MD
- Milind Desai, MD

Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM

Recommended

Title